In a small study, 1 in 3 prostate cancer patients who underwent salvage robotic-assisted radical prostatectomy following partial ablation with high-intensity focused ultrasound required adjuvant radiation or androgen deprivation therapy within 12 months.
In a study of men on active surveillance for low-risk prostate cancer, multiparametric magnetic resonance imaging by itself missed about one-fifth of men who had pathologic upgrading on subsequent biopsies.
Combining PSA density with prostate MRI findings improves the predictive performance of PI-RADS in men without a prior prostate cancer diagnosis.
Use of a gonadotropin-releasing hormone antagonist is associated with lower risks for death than GnRH agonists, a systematic review and meta-analysis found.
Research findings from ESMO confirm that patients with cancer can improve their symptoms of CRF if they “avoid inactivity”; in addition, greater use of supportive care can also help.
Confirmatory biopsy with MRI guidance provides a more accurate risk assessment than a conventional transrectal ultrasound confirmatory biopsy, according to researchers.
A new analysis looking at the effect of PSA screening on prostate cancer mortality over a 25-year period found a more favorable balance of benefits and harms than the 16-year estimates from the European Randomized Study of Screening for Prostate Cancer.
Three major medical organizations have issued recommendations for the diagnosis and treatment of advanced prostate cancer, including metastatic hormone-sensitive disease and nonmetastatic and metastatic castration-resistant disease.
A population-based Italian study found that among men with prostate cancer, those not receiving androgen deprivation therapy had significant 4-fold increased odds of testing positive for SARS-CoV-2 than those receiving ADT.
A panel of experts agreed that men with metastatic prostate cancer may be the most appropriate candidates for comprehensive genetic testing.
